Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives
Cancer Treatment Reviews · 2024-06 · 127 · 102746
DOI: 10.1016/j.ctrv.2024.102746 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Treatment Reviews, 2024-06. Verfasst von Pablo Jiménez-Labaig und 9 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, National Institute of Health Re…. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: The Royal Marsden NHS Foundation Trust.
Abstract (Originalsprache)
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) presents an ideal scenario for intratumoral therapies (IT), due to its local recurrence pattern and frequent superficial extension. IT therapies aim to effect tumor regression by directly injecting antineoplastic agents into lesions. However, there is a lack of updated evidence regarding IT therapies in HNSCC. PATIENTS AND METHODS: A systematic literature search (CRD42023462291) was conducted using WebOfScience, ClinicalTrials.gov, and conference abstracts from ESMO and ASCO, identifying for IT clinical trials in patients with HNSCC, from database creation to September 12th, 2023. Efficacy as well as safety (grade ≥ 3 treatment-related adverse events[trAEs]) were reported. RESULTS: After evaluation of 1180 articles identified by the systematic search, 31 studies treating 948 patients were included. IT injectables were categorized as chemotherapies with or without electroporation (k = 4, N = 268), oncolytic viruses, plasmids, and bacteria-based (k = 16, N = 446), immunotherapies and EGFR-based therapies (k = 5, N = 160), radioenhancer particles (k = 2, N = 68), and calcium electroporation (k = 1, n = 6). EGFR-antisense plasmids, NBTXR3 radioenhancer and immune innate agonists show best overall response rates, at 83 %, 81 % and 44 % respectively. Eleven (35 %) studies added systemic therapy or radiotherapy to the IT injections. No study used predictive biomarkers to guide patient selection. 97 % studies were phase I-II. Safety-wise, electroporation and epinephrine-based injectable trials had significant local symptoms such as necrosis, fistula formation and post-injection dysphagia. Treatment-related tumor haemorrhages of various grades were described in several trials. Grade ≥ 3 trAEs attributable to the other therapies mainly comprised general symptoms such as fatigue. There were 3 injectable-related deaths across the systematic review. CONCLUSION: This is the first review to summarize all available evidence of IT in HNSCC. As of today, IT therapies lack sufficient evidence to recommend their use in clinical practice. Continuing research on potential molecules, patient selection, safe administration of injections and controlled randomized trials are needed to assess their added benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, National Institute of Health Research Biomedical Research Centre, London, United Kingdom.
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Lung and Head & Neck Tumors Unit, Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Early Phase Clinical Trials Unit (UITM), Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
- START Madrid-FDJ, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
- Department of Radiology, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
- The Institute of Cancer Research, National Institute of Health Research Biomedical Research Centre, London, United Kingdom.
Förderung
- The Royal Marsden NHS Foundation Trust
Zitieren
APA
Jiménez-Labaig, P., Rullan, A., Braña, I., Hernando-Calvo, A., Moreno, V., Doger, B., Bitar, G., Ap Dafydd, D., Melcher, A., & Harrington, K. J. (2024). Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives. Cancer Treatment Reviews, 127, 102746. https://doi.org/10.1016/j.ctrv.2024.102746
Vancouver
Jiménez-Labaig P, Rullan A, Braña I, Hernando-Calvo A, Moreno V, Doger B, et al. Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives. Cancer Treatment Reviews. 2024;127:102746. doi:10.1016/j.ctrv.2024.102746
BibTeX
@article{JimnezLabaig2024,
author = {Jiménez-Labaig, Pablo and Rullan, Antonio and Braña, Irene and Hernando-Calvo, Alberto and Moreno, Victor and Doger, Bernard and Bitar, George and Ap Dafydd, Derfel and Melcher, Alan and Harrington, Kevin J},
title = {Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives},
journal = {Cancer Treatment Reviews},
year = {2024},
volume = {127},
pages = {102746},
doi = {10.1016/j.ctrv.2024.102746}
}
EUVIMED